Amylin Pharmaceuticals Inc. introduces a third diabetes treatment with the recent FDA approval of Bydureon, which is the first and only once-weekly treatment for type 2 diabetes.

Amylin Pharmaceuticals Inc. introduces a third diabetes treatment with the recent FDA approval of Bydureon, which is the first and only once-weekly treatment for type 2 diabetes.

AMYLIN PHARMACEUTICALS INC.

CEO: Daniel M. Bradbury.

Revenue: $650.7 million in 2011; $651.1 million in 2010.

Net loss: $543.4 million in 2011; $152.3 million in 2010.

No. of local employees: 650.

Headquarters: San Diego.

Year founded: 1987.

Stock symbol and exchange: AMLN on Nasdaq.

Company description: A biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of innovative medicines.

Key factors for success: Amylin has brought to market three therapies for the treatment of diabetes. Its two first-in-class diabetes treatments Byetta injection and Symlin injection and the first once-weekly diabetes treatment Bydureon are helping patients better control their disease. Amylin’s pipeline is focused on bringing treatment options to patients with metabolic disorders, including the life-threatening, ultra-orphan disease lipodystrophy.

Speculation continues about whether San Diego-based Amylin Pharmaceuticals Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • NEW: San Diego 500 — influential business leaders you need to know
Yours for only $129